Please select the eligibility criteria that correspond to the clinical trial below.
Title: Computer-Based Therapy for Mild Cognitive Impairment
Brief Summary: The purpose of this study is to determine the neuropsychological and neurophysiological impacts of a computer-based training program designed to improve the cognitive performance of patients with mild cognitive impairment (MCI).


Options:
A: Inclusion Criteria:

* aged 60-77 years
* dementia Risk Score 6 points or more
* fulfillment of at least one of the following CERAD criteria: i) MMSE: 20-26 points ii) word list memory task (3x10 words): 19 words or less iii) delayed recall: 75% or less

Exclusion Criteria:

* malignant diseases
* dementia
* substantial cognitive decline
* major depression
* symptomatic cardiovascular disease
* revascularisation within 1 year
* severe loss of vision, hearing or communicative ability
* other conditions inhibiting from safe engagement in the prescribed intervention as judged by the study physician
* other conditions preventing from cooperation as judged by the study physician
B: Inclusion Criteria:

1)65 - 90 years of age 2)Meet definition for MCI including complaints of cognitive decline as indicated by patient report and/or informant report, and corroborated by clinician judgment and, the absence of dementia, defined as impairment of memory and at least one other domain of cognitive function.

3)Fluency in English 4)Willing to meet the time commitment of the study

-

Exclusion Criteria:

1. Clinically significant cerebrovascular disease
2. Individuals scheduled to begin acetylcholinesterase inhibitor (AChEI) therapy -
C: Inclusion Criteria:

* Male or female patients aged ≥ 55 years, fulfilling criteria of the National Institute of Neurological and Communicative Disease and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) for the diagnosis of clinically probable AD or Petersen's criteria of mild cognitive impairment (MCI)
* No evidence for other psychiatric axis I disorders according to DSM-IV criteria
* No uncontrolled arterial hypertension or diabetes mellitus
* No history of drug/alcohol abuse
* Cholinesterase inhibitors or Memantine must have been in a stabile doses at least 2 moths in AD subject group prior to the Baseline
* The patient is able to provide written informed consent to participate in the study. If, at investigator's discretion, a patient is considered not to be capable to give legal consent, then written consent must also be obtained from the patient's legally acceptable representative.

Exclusion Criteria:

* Evidence for other psychiatric axis I disorders according to DSM-IV criteria
* Uncontrolled arterial hypertension or diabetes mellitus
* History of drug/alcohol abuse
* No ability to participate and no willing to give informed consent and comply with the study restrictions
D: Inclusion Criteria:

* Age 65 or older
* Mini-Mental State Examination (MMSE) score 23 or greater
* Vision scored greater than 20/50
* Minimal dependence in hygiene, bathing, and dressing

Exclusion Criteria:

* Significant decline in cognitive skills, physical abilities, or functional independence
* Inability to complete study activities as evidenced by MMSE and vision scores lower than Inclusion Criteria requirement
* Diagnosis of Alzheimer's disease
* Stroke in previous 12 months
* Cancer with limited life expectance
* Current chemotherapy or radiation treatment
* Communication problems
* Planned move from study area
* Scheduling conflicts that would preclude participation in study activities
* Prior involvement in similar cognitive training studies

Answer: B